The latest funding rounds, like BrightHeart’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New funding rounds, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Industry Trends
See who's moving and how much in your market
No credit card required Weekly funding digest
BrightHeart raises €11 million in Series A funding to commercialize its B-Right AI Prenatal Ultrasound platform across Europe, leveraging advanced technology to improve prenatal diagnoses.
Paris-based BrightHeart has received the CE mark for its B-Right AI Platform, allowing it to be commercialized in the European Union. This funding round of €11 million will support the launch and expansion of their technology. The platform aims to improve detection of fetal structural defects, addressing a significant public health challenge. BrightHeart will showcase its technology at the FMF World Congress in Vienna from June 28 to July 2, 2026.
Company Information
Company
BrightHeart
Location
Paris, Ile De France, France
About
BrightHeart is a Paris-based, privately held, pre-clinical medical device company and part of Sofinnova MD Start, Sofinnova Partners' medical device accelerator. The company’s software uses cutting-edge artificial intelligence to analyze fetal heart ultrasound exams and support clinicians with the prenatal identification of congenital heart defects. The technology aims to improve pregnancy outcomes by anticipating delivery care and early intervention.
Predictive Intelligence
Strategic
ML-powered predictions for BrightHeart's next move
ParisBiotechnologyHealth CareArtificial IntelligenceMedicalMedical Device